Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR8 | P51685 | 7/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.44 |
| ▸ | HRH2 | P25021 | 1/20 | 0.44 |
| ▸ | HRH1 | P35367 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 1/20 | 0.40 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.40 |
| ▸ | SFRP1 | Q8N474 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2401724 | 1.00 | CCR8 (0.52) | CCR8ALDH1A1HSD11B1HRH2HRH1 | |
| SCHEMBL2403258 | 0.89 | ALDH1A1 (0.53) | CCR8ALDH1A1HRH2HRH1HRH3 | |
| SCHEMBL2405226 | 0.89 | ALDH1A1 (0.53) | CCR8ALDH1A1HRH2HRH1HRH3 | |
| SCHEMBL2403265 | 0.89 | ALDH1A1 (0.53) | CCR8ALDH1A1HRH2HRH1HRH3 | |
| SCHEMBL2401728 | 0.88 | DRD2 (0.48) | CCR8ALDH1A1HSD11B1HRH2HRH1 | |
| SCHEMBL2401730 | 0.88 | DRD2 (0.48) | CCR8ALDH1A1HSD11B1HRH2HRH1 | |
| SCHEMBL2405887 | 0.86 | CCR8 (0.53) | CCR8ALDH1A1HSD11B1HRH2HRH1 | |
| SCHEMBL2405883 | 0.86 | CCR8 (0.53) | CCR8ALDH1A1HSD11B1HRH2HRH1 | |
| SCHEMBL2405892 | 0.85 | USP30 (0.50) | CCR8HSD11B1HRH3KCNH2DPP4 | |
| SCHEMBL2403253 | 0.85 | ATM (0.53) | CCR8ALDH1A1HRH2HRH1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8017773-B2 | Cyclohexyl sulfonamide derivatives | HOFFMANN-LA ROCHE INC. (US) | 2011-09-13 | — | — | US | claimed |
| EP-1979322-B1 | CYCLOHEXYL SULFONAMIDE DERIVATIVES HAVING H3 RECEPTOR ACTIVITY | HOFFMANN LA ROCHE (CH) | 2010-09-01 | — | — | EP | claimed |
| US-20100120791-A1 | CYCLOHEXYL SULFONAMIDE DERIVATIVES | NETTEKOVEN MATTHIAS | 2010-05-13 | — | — | US | claimed |
| US-20070173511-A1 | Cyclohexyl sulfonamide derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2007-07-26 | — | — | US | claimed |
| US-8017773-B2 | Cyclohexyl sulfonamide derivatives | HOFFMANN-LA ROCHE INC. (US) | 2011-09-13 | — | — | US | disclosed |
| EP-1979322-B1 | CYCLOHEXYL SULFONAMIDE DERIVATIVES HAVING H3 RECEPTOR ACTIVITY | HOFFMANN LA ROCHE (CH) | 2010-09-01 | — | — | EP | disclosed |
| US-20100120791-A1 | CYCLOHEXYL SULFONAMIDE DERIVATIVES | NETTEKOVEN MATTHIAS | 2010-05-13 | — | — | US | disclosed |
| US-20070173511-A1 | Cyclohexyl sulfonamide derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2007-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120791-A1 | CYCLOHEXYL SULFONAMIDE DERIVATIVES | HRH3, HRH4, HRH1 | CCR8 1481/4885ALDH1A1 430/4885HSD11B1 1268/4885 |
| US-20070173511-A1 | Cyclohexyl sulfonamide derivatives | HRH3, HRH4, HRH1 | CCR8 1481/4885ALDH1A1 430/4885HSD11B1 1268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.